The FDA's Fast Track designation helps to accelerate the development and review of products for serious and life-threatening conditions.

Bacteria in head and neck tumor stimulate immunotherapy resistance by attracting immune cells and creating a shield. Targeting microbiome is a key.

SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, ...

TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses ...

Head and neck cancer trials are frequently derailed before they can deliver answers. A new analysis suggests that the most ...

Head and neck cancers represent 4% of U.S. cancer cases, with significant mortality rates, highlighting the need for awareness and early detection. These cancers affect multiple anatomical sites, ...

Adding neoadjuvant and adjuvant pembrolizumab to the standard of care significantly improved event-free survival in patients with previously untreated, locally advanced head and neck squamous cell ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain head and neck cancers from returning. Continuous use of Keytruda—both ...

Head and neck cancer is a broad term for several types of cancers that include the mouth (oral cavity), throat (pharynx), voice box (larynx), sinuses and nose cavity, and salivary glands. Head and ...